1,3,4-oxadiazole conjugates of capsaicin as potent NorA efflux pump inhibitors of Staphylococcus aureus.
Anti-Bacterial Agents
/ chemical synthesis
Bacterial Proteins
/ antagonists & inhibitors
Binding Sites
Capsaicin
/ chemistry
Cell Line, Tumor
Cell Survival
/ drug effects
Ciprofloxacin
/ pharmacology
Drug Resistance, Multiple, Bacterial
/ drug effects
Humans
Kinetics
Microbial Sensitivity Tests
Molecular Docking Simulation
Multidrug Resistance-Associated Proteins
/ antagonists & inhibitors
Oxadiazoles
/ chemistry
Staphylococcus aureus
/ drug effects
Structure-Activity Relationship
Capsaicin
Cytotoxicity
Molecular docking and MD simulation
NorA efflux pump
Oxadiazole
S. aureus
Journal
Bioorganic chemistry
ISSN: 1090-2120
Titre abrégé: Bioorg Chem
Pays: United States
ID NLM: 1303703
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
12
03
2021
revised:
11
05
2021
accepted:
24
05
2021
pubmed:
6
6
2021
medline:
26
10
2021
entrez:
5
6
2021
Statut:
ppublish
Résumé
NorA efflux pump pertaining to the major facilitator superfamily (MFS) is known to play a key role in antibiotic and biocide resistance in Staphylococcus aureus (S. aureus). It accounts for the extrusion of antibiotics like fluoroquinolones (e.g. ciprofloxacin). Several compounds including synthetic and natural products have been identified as potential NorA efflux pump inhibitors (EPIs) and found to restore the antibacterial activity of antibiotics. However, none of the reported EPIs have reached to clinical approval probably due to their high toxicity profiles. Considering the NorA efflux pump inhibitory potential of capsaicin, a series of capsaicin-based 1,3,4 oxadiazole conjugates were prepared and evaluated for ciprofloxacin activity potentiating effect. Among the new capsaicinoids tested, 17i displayed a minimum effective concentration (MEC) of 12.5 µg/mL against NorA overexpressing S. aureus strain (SA1199B), whereas capsaicin showed MEC of 50 µg/mL. The kill kinetics curve for the combination showed that ciprofloxacin at a sub-inhibitory concentration (0.25 × MIC) was equipotent in effect, to its MIC. 17i has significantly decreased the ethidium bromide efflux confirming NorA inhibition as the mode of action. Mutation prevention concentration of the ciprofloxacin was reduced in combination with 17i.In silico studies revealed the binding efficiency and binding affinity of 17i with NorA. This compound may serve as a template for the further drug discovery.
Identifiants
pubmed: 34089943
pii: S0045-2068(21)00408-9
doi: 10.1016/j.bioorg.2021.105031
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Bacterial Proteins
0
Multidrug Resistance-Associated Proteins
0
Oxadiazoles
0
NorA protein, Staphylococcus
133135-40-7
1,3,4-oxadiazole
20O2F20OUR
Ciprofloxacin
5E8K9I0O4U
Capsaicin
S07O44R1ZM
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
105031Informations de copyright
Copyright © 2021. Published by Elsevier Inc.